A variety of metabolic disease states as well as the ageing process are characterised with a state of low-gradechronic inflammation, which may contribute to skeletal muscle wasting. Since muscle wasting is associated with increases in morbidity and all-cause mortality, targeting of skeletal muscle inflammation may prove a useful therapeutic tool to enable the preservation of skeletal muscle mass in disease states categorised by chronic low-grade inflammation. One potential avenue for intervention is via nutritional intervention, omega-3fatty acids have been implicated to have anti-inflammatory properties mediated via a variety of mechanisms. One such mechanism is through a group of bioactive lipid mediators produced in inflammatory states via the metabolism of both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which aretermed specialised pro-resolving mediators (SPM's).